Terms: = Lymphoma AND NRG1, ENSG00000157168, 3084, SMDF, NDF, HRGA, HRG1, HGL, GGF2, GGF, ARIA AND Treatment
12 results:
1. Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.
Xiao L; Liu Y; Chen H; Shen L
Cancer Biol Ther; 2023 Dec; 24(1):2219470. PubMed ID: 37272701
[TBL] [Abstract] [Full Text] [Related]
2. First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.
Diamond JR; Boni V; Lim E; Nowakowski G; Cordoba R; Morillo D; Valencia R; Genvresse I; Merz C; Boix O; Frigault MM; Greer JM; Hamdy AM; Huang X; Izumi R; Wong H; Moreno V
Clin Cancer Res; 2022 Apr; 28(7):1285-1293. PubMed ID: 35046056
[TBL] [Abstract] [Full Text] [Related]
3. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
Melosky B; Wheatley-Price P; Juergens RA; Sacher A; Leighl NB; Tsao MS; Cheema P; Snow S; Liu G; Card PB; Chu Q
Lung Cancer; 2021 Oct; 160():136-151. PubMed ID: 34353680
[TBL] [Abstract] [Full Text] [Related]
4. Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers.
Tan AC; Itchins M; Khasraw M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093103
[TBL] [Abstract] [Full Text] [Related]
5. Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin lymphoma.
Hijazi Y; Klinger M; Kratzer A; Wu B; Baeuerle PA; Kufer P; Wolf A; Nagorsen D; Zhu M
Curr Clin Pharmacol; 2018; 13(1):55-64. PubMed ID: 29773068
[TBL] [Abstract] [Full Text] [Related]
6. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
Dong X; Fernandez-Salas E; Li E; Wang S
Neoplasia; 2016 Mar; 18(3):162-71. PubMed ID: 26992917
[TBL] [Abstract] [Full Text] [Related]
7. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma.
Kamath SS; Marcus RB; Lynch JW; Mendenhall NP
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):563-8. PubMed ID: 10348285
[TBL] [Abstract] [Full Text] [Related]
8. [Non-Hodgkin's lymphomas. II. Analysis of the prognostic factors in a series of 307 patients].
García Zueco JC; Delgado MP; Giraldo MP; Perella M; Rubio-Félix D; Giralt M
Sangre (Barc); 1992 Oct; 37(5):337-44. PubMed ID: 1293772
[TBL] [Abstract] [Full Text] [Related]
9. Cutaneous lymphomas other than mycosis fungoides: follow-up study of 52 patients.
Joly P; Charlotte F; Leibowitch M; Haioun C; Wechsler J; Dreyfus F; Escande JP; Revuz J; Reyes F; Varet B
J Clin Oncol; 1991 Nov; 9(11):1994-2001. PubMed ID: 1941058
[TBL] [Abstract] [Full Text] [Related]
10. Accumulation of O6-methylguanine in human blood leukocyte DNA during exposure to procarbazine and its relationships with dose and repair.
Souliotis VL; Kaila S; Boussiotis VA; Pangalis GA; Kyrtopoulos SA
Cancer Res; 1990 May; 50(9):2759-64. PubMed ID: 2328502
[TBL] [Abstract] [Full Text] [Related]
11. Conversion of high grade lymphoma tumor cell line to intermediate grade with TPA and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis.
al-Katib A; Mohammad RM; Mohamed AN; Pettit GR; Sensenbrenner LL
Hematol Oncol; 1990; 8(2):81-9. PubMed ID: 2344999
[TBL] [Abstract] [Full Text] [Related]
12. High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma.
Petersen FB; Appelbaum FR; Bigelow CL; Buckner CD; Clift RA; Sanders JE; Storb R; Sullivan KM; Weiden PL; Fefer A
Bone Marrow Transplant; 1989 Sep; 4(5):483-8. PubMed ID: 2676043
[TBL] [Abstract] [Full Text] [Related]
